The Biden administration’s push to introduce widespread Covid-19 vaccine boosters faces a test as a Food and Drug Administration advisory panel meets to weigh evidence on the extra shots, a topic that has divided federal health officials.
The outside panel of about 20 scientific advisers was meeting Friday to review information Friday about the Pfizer Inc. and BioNTech SE vaccine’s declining protection against Covid-19 over time and on how people tolerated additional doses. It will hear presentations from Pfizer, which has asked regulators to clear booster shots for people 16 years and older, and the FDA, which this week said all the shots cleared for use in the U.S. remain effective without boosters. The panel will also consider contrasting scientific data about the extra shots.
